In loving memory of Thomas Hartle, who left us one year ago today, on August 13th.
When I first spoke with Dr. Valorie Masuda in 2022, I had this conversation with Thomas not long after.
After releasing our recent podcasts from the (first) doctor's perspective of psilocybin assisted therapy for end of life distress, it's only right we share the first patient's experience.
Thomas was so open and vulnerable that it's hard to not feel emotions listening to him share his story.
His legacy lives on as more and more patients receive access to psilocybin therapy who desperately need it.
If you are looking to learn more about psychedelic therapy as a health practitioner or are looking for this treatment for yourself, please reach out to @TheraPsil for more information.
❤️❤️❤️
More details:
Thomas Hartle became the first Canadian to receive psilocybin assisted therapy legally through Health Canada's Section 56 exemption program. Diagnosed with stage 4 cancer in 2016, Thomas underwent 78 rounds of chemotherapy throughout his journey, experienced remission, then faced another tumor recurrence that sparked severe end-of-life anxiety.
After finding the Johns Hopkins psilocybin study showing 80% success rates for existential distress, Thomas applied for legal access through TheraPsil organization. His anxiety score dropped dramatically from 36 to 6 after his first heroic dose treatment with Dr Bruce Tobin. He's now completed six legal psilocybin therapy sessions using both Section 56 exemption and Special Access Program pathways.
Our conversation goes into Thomas's cancer journey starting with an initial Crohn's disease misdiagnosis, multiple surgeries including ileostomy, HIPEC heated intraperitoneal chemotherapy, and his ongoing palliative care. Thomas talks about dealing with chemotherapy side effects, how he recovered from neuropathy using lion's mane mushrooms, and various adjuvant treatments like turkey tail mushrooms he discovered through PubMed research.
He walks us through his actual psychedelic experience - the ego dissolution, consciousness expansion, preparatory sessions, integration therapy, and set and setting protocols. His treatments had him blindfolded with headphones on listening to the Johns Hopkins playlist, guided psychedelic sessions, and safety monitoring by medical practitioners.
We get into the healthcare bureaucracy challenges, patient advocacy work, and Thomas's charter challenge against Health Canada's restrictive policies. There's discussion about clinical trials versus compassionate access, treatment-resistant depression applications, and psilocybin therapy training for practitioners.
Thomas opens up about spirituality versus religion, consciousness after psychedelic experiences, and the increased empathy he felt after treatment. We talk about pharmaceutical industry models, patient rights advocacy, and where the psychedelic medicine movement is headed in Canadian healthcare.
The conversation also covers autism spectrum parenting anxiety, caregiver stress, survivor's guilt, family support systems, and end-of-life care alternatives. Thomas explains his work with TheraPsil, training new therapists, and why he documented his sessions for educational purposes.
What really stands out is the contrast between having Medical Assistance in Dying readily available while anxiety-reducing psilocybin therapy remains so restricted for terminal patients. Thomas advocates for medicalization rather than full legalization, focusing on therapeutic applications over recreational use.
We cover a lot of ground including Dr Valorie Masuda's work, Minister of Health Carolyn Bennett, psychedelic synesthesia, macro-dose versus micro-dosing, oncology mental health, harm reduction, neurogenesis, meditation practices, preparatory therapy, integration sessions, Saskatoon clinical access, and Jamaica retreat experiences.